The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked Robert F.

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Manila Water Foundation Joins Erceflora Probiotics and Save the Children Philippines to Expand Hygiene and Water Access for ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

If confirmed as the HHS Secretary by the US Senate, RFK Jr will oversee federal agencies that dictate healthcare policy in ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...